Chronic Urticaria Or Hives - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Chronic Urticaria Or Hives - Pipeline Review, H2 2018’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives

- The report reviews pipeline therapeutics for Chronic Urticaria Or Hives by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Chronic Urticaria Or Hives therapeutics and enlists all their major and minor projects

- The report assesses Chronic Urticaria Or Hives therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

BiosanaPharma BV

ELORAC Inc

F. Hoffmann-La Roche Ltd

Faes Farma SA

Fountain Biopharma Inc

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

JHL Biotech Inc

Mycenax ...

BiosanaPharma BV

ELORAC Inc

F. Hoffmann-La Roche Ltd

Faes Farma SA

Fountain Biopharma Inc

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

JHL Biotech Inc

Mycenax Biotech Inc

Novartis AG

Synermore Biologics Co Ltd

United BioPharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Urticaria Or Hives - Overview

Chronic Urticaria Or Hives ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Urticaria Or Hives - Overview

Chronic Urticaria Or Hives - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Urticaria Or Hives - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development

BiosanaPharma BV

ELORAC Inc

F. Hoffmann-La Roche Ltd

Faes Farma SA

Fountain Biopharma Inc

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

JHL Biotech Inc

Mycenax Biotech Inc

Novartis AG

Synermore Biologics Co Ltd

United BioPharma Inc

Chronic Urticaria Or Hives - Drug Profiles

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetirizine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cidoxepin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fenebrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ligelizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LOU-064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-221 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Urticaria Or Hives - Dormant Projects

Chronic Urticaria Or Hives - Discontinued Products

Chronic Urticaria Or Hives - Product Development Milestones

Featured News & Press Releases

Sep 28, 2018: FDA approves Genentech Xolair (Omalizumab) prefilled syringe formulation

Mar 06, 2018: Novartis' Xolair recommended in new global chronic urticaria guideline

Sep 16, 2017: Novartis Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption

Jun 20, 2017: Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden

Jun 19, 2017: Xolair added to seven Canadian public drug plans to treat chronic idiopathic urticaria (hives)

Mar 24, 2017: Anti-IgE antibody formulation "Zolare" acquired additional indication as a treatment for idiopathic chronic urticaria

Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada

Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan

Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan

Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN

Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan

Jun 12, 2015: Novartis reports new analysis showing Xolair improving quality of life by 78% for chronic spontaneous urticaria patients

May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration

Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines

May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H2 2018

Number of Products under Development by Companies, H2 2018

Products ...

List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chronic Urticaria Or Hives - Pipeline by BiosanaPharma BV, H2 2018

Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H2 2018

Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H2 2018

Chronic Urticaria Or Hives - Pipeline by Fountain Biopharma Inc, H2 2018

Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H2 2018

Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2018

Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018

Chronic Urticaria Or Hives - Pipeline by JHL Biotech Inc, H2 2018

Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H2 2018

Chronic Urticaria Or Hives - Pipeline by Novartis AG, H2 2018

Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H2 2018

Chronic Urticaria Or Hives - Pipeline by United BioPharma Inc, H2 2018

Chronic Urticaria Or Hives - Dormant Projects, H2 2018

Chronic Urticaria Or Hives - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Chronic Urticaria Or Hives, H2 2018

Number of Products under Development by Companies, H2 2018

Number ...

List of Figures

Number of Products under Development for Chronic Urticaria Or Hives, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports